Coronary Artery Disease And Melatonin: The Mechanisms and Therapeutic Applications

Abstract

Delaying the formation of atherosclerosis and reducing cardiac ischemia-reperfusion injury remain pressing issues. Melatonin (MLT) possesses anti-inflammatory and antioxidant properties, rendering it a promising candidate for clinical application in coronary artery disease (CAD) patients. While numerous in vivo experiments have elucidated the regulatory mechanisms of MLT in animal models and clinical trials have preliminarily demonstrated the excellent therapeutic potential of MLT in CAD, several key questions remain unanswered. In this review, the authors elucidate the mechanisms underlying CAD's occurrence, progression, and prognosis; delineate the pathways through which MLT exerts its effects; and present compelling evidence supporting its efficacy in CAD. In addition, the authors also describe unresolved issues in the treatment of CAD with MLT, thus providing scholars with directions for future research.